EHA 2018 | Fecal transplants as salvage therapy for acute refractory GvHD
Allogenic stem cell transplants are the only curative therapy available for several hematological diseases; however, graft-versus-host disease (GvHD) is a common complication of this procedure. The accepted first-line treatment for GvHD is corticosteroids, but patients who do not respond to this treatment generally have poor outcomes. In this video, recorded at the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France, speaks about a revolutionary second-line treatment for acute refractory GvHD: fecal transplants. He discusses the HERACLES trial (NCT03359980), and the important role of gut microbiome diversity in allotransplant patients.
Get great new content delivered to your inboxSign up